HKeyBio Cuts NHP Autoimmune Model Prices Despite 180% Cost Surge
Event summary
- HKeyBio slashed prices on NHP autoimmune disease models by 10%-30% despite a 180% increase in NHP procurement costs since 2022.
- NHP costs surged from ~USD 12,000 in 2022 to over USD 28,000 in 2026.
- The move aims to support biotech R&D during the global funding winter.
- HKeyBio will absorb rising NHP acquisition costs to maintain service affordability.
The big picture
HKeyBio's counter-cyclical pricing strategy addresses a critical bottleneck in autoimmune drug development amid a global NHP shortage. The move positions the company as a resilient partner in the biotech ecosystem, potentially broadening its industry footprint during a challenging funding environment. The initiative underscores the symbiotic relationship between CROs and biotech innovators, emphasizing the need for collaborative solutions in preclinical research.
What we're watching
- Cost Absorption Sustainability
- Whether HKeyBio can maintain price reductions amid continuing NHP cost volatility.
- Industry Adoption
- The pace at which biotech firms leverage HKeyBio's counter-cyclical pricing for revived projects.
- Long-Term Positioning
- How HKeyBio's strategy affects its market share and translational database growth.